* Inovio Pharmaceuticals Inc INO.OQ reported a quarterly
adjusted loss of $1.31 per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-1.92. The mean expectation of five analysts
for the quarter was for a loss of 100 cents per share. Wall
Street expected results to range from $-1.17 to -86 cents per
share.
* Reported revenue was zero; analysts expected $150.80
thousand.
* Inovio Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.31.
* The company reported a quarterly loss of $30.47 million.
* Inovio Pharmaceuticals Inc shares had fallen by 23.3% this
quarter and gained 74.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 21.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Inovio
Pharmaceuticals Inc is $14.50
This summary was machine generated from LSEG data May 13 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.00 -1.31 Missed
Dec. 31 2023 -1.27 -1.12 Beat
Sep. 30 2023 -1.52 -1.56 Missed
Jun. 30 2023 -1.74 -1.56 Beat